Reports
| Status | Drug name | NICE TAs | Comments |
|---|---|---|---|
 |
Oxybutynin patch (Kentera) | If first line is not tolerated, following specialist advice |
|
|
Oxycodone hydrochloride capsules | Lynlor capsules preferred brand |
|
|
Oxycodone hydrochloride M/R tablets | Reltebon MR tablets preferred brand |
|
|
Oxycodone hydrochloride SF solution | ||
|
Oxygen | Long term use - requires specialist assessment |
|
|
Pancrex V® powder | ||
|
Paraldehyde rectal solution 50% in olive oil (10ml) | ||
|
Penecillamine tablets | ESCA |
|
|
Penicillamine | Specialist recommendation for Wilson disease. Supported with an ESCA (in development). |
|
|
Pentasa 1g suppositories |
Drug status key
Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.
Grey
Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.
Red
Initiation and maintenance of prescribing by specialists only.
Amber
Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.
Green
Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.
Blue
Under review at University Hospitals Birmingham NHS Foundation Trust.
